{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:23:29Z","timestamp":1790702609932,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/Multi\/04349\/2019"],"award-info":[{"award-number":["UID\/Multi\/04349\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/BTM-TEC\/29256\/2017"],"award-info":[{"award-number":["PTDC\/BTM-TEC\/29256\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04565\/2020"],"award-info":[{"award-number":["UIDB\/04565\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Prostate cancer (PCa) is the second most common cancer type in men, and in advanced metastatic stages is considerable incurable. This justifies the need for efficient early diagnostic methods and novel therapies, particularly radiopharmaceuticals with the potential for simultaneous diagnosis and therapy (theranostics). We have previously demonstrated, using monolayer-cultured cells, that copper-64 chloride, a promising theranostic agent for PCa, has the potential to induce significant damage in cancer cells while having minimal side effects in healthy tissues. Here, we further explored this compound for its theranostic applications using more advanced PCa cellular models, specifically multicellular spheroids. Namely, we evaluated the cellular uptake of <jats:sup>64<\/jats:sup>CuCl<jats:sub>2<\/jats:sub> in three human PCa spheroids (derived from 22RV1, DU145, and LNCaP cells), and characterized the growth profile and viability of those spheroids as well as the clonogenic capacity of spheroid-derived cells after exposure to <jats:sup>64<\/jats:sup>CuCl<jats:sub>2<\/jats:sub>. Furthermore, the populations of cancer stem cells (CSCs), known to be important for cancer resistance and recurrence, present in the spheroid models were also evaluated using two different markers (CD44 and CD117). <jats:sup>64<\/jats:sup>CuCl<jats:sub>2<\/jats:sub> was found to have significant detrimental effects in spheroids and spheroid-derived cells, being able to reduce their growth and impair the viability and reproductive ability of spheroids from both castration-resistant (22RV1 and DU145) and hormone-na\u00efve PCa (LNCaP). Interestingly, resistance to <jats:sup>64<\/jats:sup>CuCl<jats:sub>2<\/jats:sub> treatment seemed to be related with the presence of a CSC population, since the most resistant spheroids, derived from the DU145 cell line, had the highest initial percentage of CSCs among the three cell lines under study. Altogether, these results clearly highlight the theranostic potential of <jats:sup>64<\/jats:sup>CuCl<jats:sub>2<\/jats:sub>.<\/jats:p>","DOI":"10.3389\/fmolb.2020.609172","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T07:28:04Z","timestamp":1606807684000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Copper-64 Chloride Exhibits Therapeutic Potential in Three-Dimensional Cellular Models of Prostate Cancer"],"prefix":"10.3389","volume":"7","author":[{"given":"Catarina I. G.","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edtor","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antero J.","family":"Abrunhosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia L.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana F.","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1142\/s0217732317400132","article-title":"Production of copper\u201364 and gallium\u201368 with a medical cyclotron using liquid targets.","volume":"32","author":"Alves","year":"2017","journal-title":"Mod. Phys. Lett. A"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00605","article-title":"Comparative analysis of 3D bladder tumor spheroids obtained by forced floating and hanging drop methods for drug screening.","volume":"8","author":"Amaral","year":"2017","journal-title":"Front. Physiol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00347","article-title":"Sphere-formation assay: three-dimensional","volume":"8","author":"Bahmad","year":"2018","journal-title":"Front. Oncol."},{"key":"B4","first-page":"2008","article-title":"Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).","volume":"61","author":"Ballangrud","year":"2001","journal-title":"Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.drudis.2018.04.002","article-title":"The emerging role of copper-64 radiopharmaceuticals as cancer theranostics.","volume":"23","author":"Boschi","year":"2018","journal-title":"Drug Discov. Today"},{"key":"B6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00180","article-title":"Key roles of hyaluronan and its CD44 receptor in the stemness and survival of cancer stem cells.","volume":"5","author":"Chanmee","year":"2015","journal-title":"Front. Oncol."},{"key":"B8","article-title":"High-throughput image analysis of tumor spheroids: a user-friendly software application to measure the size of spheroids automatically and accurately.","volume":"89","author":"Chen","year":"2014","journal-title":"J. Vis. Exp."},{"key":"B9","doi-asserted-by":"publisher","first-page":"10946","DOI":"10.1158\/0008-5472.can-05-2018","article-title":"Prospective identification of tumorigenic prostate cancer stem cells.","volume":"65","author":"Collins","year":"2005","journal-title":"Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158116","article-title":"Influence of matrices on 3D-cultured prostate cancer cells\u2019 drug response and expression of drug-action associated proteins.","volume":"11","author":"Edmondson","year":"2016","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2967\/jnumed.117.207308","article-title":"Targeting micrometastases: the effect of heterogeneous radionuclide distribution on tumor control probability.","volume":"60","author":"Falzone","year":"2018","journal-title":"J. Nucl. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.prp.2017.04.027","article-title":"Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma.","volume":"213","author":"Foroozan","year":"2017","journal-title":"Pathol. Res. Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/1087057107306839","article-title":"A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay.","volume":"12","author":"Friedrich","year":"2007","journal-title":"J. Biomol. Screen"},{"key":"B14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nprot.2008.226","article-title":"Spheroid-based drug screen: considerations and practical approach.","volume":"4","author":"Friedrich","year":"2009","journal-title":"Nat. Protoc."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23112944","article-title":"Radiobiological characterization of 64CuCl2 as a simple tool for prostate cancer theranostics.","volume":"23","author":"Guerreiro","year":"2018","journal-title":"Molecules"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.2147\/dddt.s170879","article-title":"Copper-64: a real theranostic agent.","volume":"12","author":"Gutfilen","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010431","article-title":"A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses.","volume":"5","author":"H\u00e4rm\u00e4","year":"2010","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.18632\/oncotarget.12554","article-title":"Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: opportunities for therapeutic targeting from multiple angles.","volume":"8","author":"Hoang","year":"2017","journal-title":"Oncotarget"},{"key":"B19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/cas.13155","article-title":"Tumor-derived spheroids: relevance to cancer stem cells and clinical applications.","volume":"108","author":"Ishiguro","year":"2017","journal-title":"Cancer Sci."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103817","article-title":"Multiplexing spheroid volume, resazurin and acid phosphatase viability assays for high-throughput screening of tumour spheroids and stem cell neurospheres.","volume":"9","author":"Ivanov","year":"2014","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s12253-016-0169-z","article-title":"Co-expression of putative cancer stem cell markers CD44 and CD133 in prostate carcinomas.","volume":"23","author":"Kalantari","year":"","journal-title":"Pathol. Oncol. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/pai.0000000000000343","article-title":"Increased expression of ALDH1A1 in prostate cancer is correlated with tumor aggressiveness: a tissue microarray study of iranian patients.","volume":"25","author":"Kalantari","year":"","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"B23","article-title":"In vitro 3D spheroids and microtissues: ATP-based cell viability and toxicity assays","author":"Kijanska","year":"2016","journal-title":"The Assay Guidance Manual"},{"key":"B24","first-page":"3429","article-title":"Differential expression of cell surface molecules in prostate cancer cells.","volume":"60","author":"Liu","year":"2000","journal-title":"Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11010-010-0426-5","article-title":"Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.","volume":"340","author":"Liu","year":"2010","journal-title":"Mol. Cell Biochem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s13277-012-0325-3","article-title":"Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines.","volume":"33","author":"Ma","year":"2012","journal-title":"Tumour Biol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00293","article-title":"High-content monitoring of drug effects in a 3D spheroid model.","volume":"7","author":"Mittler","year":"2017","journal-title":"Front. Oncol."},{"key":"B28","first-page":"242","article-title":"Cancer stem cells in prostate cancer.","volume":"2","author":"Moltzahn","year":"2013","journal-title":"Transl. Androl. Urol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pharmthera.2016.03.013","article-title":"Three-dimensional culture systems in cancer research: focus on tumor spheroid model.","volume":"163","author":"Nath","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrc3184","article-title":"Cancer stem cells: an evolving concept.","volume":"12","author":"Nguyen","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/bit.26845","article-title":"3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs.","volume":"116","author":"Nunes","year":"2019","journal-title":"Biotechnol. Bioeng."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1007\/s00261-020-02591-7","article-title":"Diagnostic value of retrospectively fused 64CuCl2 PET\/MRI in biochemical relapse of prostate cancer: comparison with fused 18F-Choline PET\/MRI, 64CuCl2 PET\/CT, 18F-Choline PET\/CT, and mpMRI.","volume":"45","author":"Paparo","year":"2020","journal-title":"Abdom Radiol. (NY)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/sj.onc.1209327","article-title":"Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.","volume":"25","author":"Patrawala","year":"2006","journal-title":"Oncogene"},{"key":"B34","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2967\/jnumed.117.195628","article-title":"64CuCl2 PET\/CT in prostate cancer relapse.","volume":"59","author":"Piccardo","year":"2018","journal-title":"J. Nuclear Med."},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-018-0373-9","article-title":"Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications.","volume":"8","author":"Righi","year":"2018","journal-title":"EJNMMI Res."},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201701174","article-title":"The current landscape of 3D in vitro tumor models: what cancer hallmarks are accessible for drug discovery?","volume":"7","author":"Rodenhizer","year":"2018","journal-title":"Adv. Healthc Mater."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221775","article-title":"Global incidence of prostate cancer in developing and developed countries with changing age structures.","volume":"14","author":"Teoh","year":"2019","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/jphp.12558","article-title":"Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.","volume":"68","author":"Tesson","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/pros.20502","article-title":"Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates.","volume":"66","author":"Wang","year":"2006","journal-title":"Prostate"},{"key":"B40","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4161\/cbt.6.5.3996","article-title":"Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?","volume":"6","author":"Wei","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"B41","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.biocel.2012.08.022","article-title":"Cancer stem cells.","volume":"44","author":"Yu","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1038\/srep19103","article-title":"3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained.","volume":"6","author":"Zanoni","year":"2016","journal-title":"Sci. Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00432-011-1146-2","article-title":"Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties.","volume":"138","author":"Zhang","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2020.609172\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T07:28:09Z","timestamp":1606807689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2020.609172\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":43,"alternative-id":["10.3389\/fmolb.2020.609172"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2020.609172","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]},"article-number":"609172"}}